Amendments To the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (canceled).

4. (currently amended) The compound of Claim ~~3~~ 37 of the formula Id:



Id

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

5. (canceled).

6. (currently amended) The compound of Claim ~~3~~ 37 of the formula If:



If

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

Claims 7-14 (canceled).

15. (currently amended) The compound of Claim ~~1~~ 37 wherein Z is -C- or -N-.

16. (currently amended) The compound of Claim ~~1~~ 37 wherein n is 0 ~~and~~ or 1.

17. (currently amended) The compound of Claim ~~1~~ 37 wherein m is 1.

Claims 18-24 (canceled).

25. (currently amended) The compound of Claim ~~1~~ 37 wherein R^2 is selected from:

(1) -CH_2-(phenyl),
(2) -CH_2-(4-bromophenyl),
(3) -CH_2-(3-chlorophenyl),
(4) -CH_2-(3,5-difluorophenyl),
(5) -CH_2-((2-trifluoromethyl)phenyl),
(6) -CH_2-((3-trifluoromethyl)phenyl),
(7) -CH_2-((4-trifluoromethyl)phenyl),
(8) -CH_2-((3-trifluoromethoxy)phenyl),
(9) -CH_2-((3-trifluoromethylthio)phenyl),
(10) -CH_2-((3-trifluoromethoxy-5-thiomethyl)phenyl),
(11) -CH_2-((3-trifluoromethoxy-5-methoxy)phenyl),
(12) -CH_2-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),
(13) -CH_2-((3-trifluoromethoxy-5-amino)phenyl),
(14) -CH_2-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),
(15) -CH_2-((3-trifluoromethoxy-5-sulfonylamino)phenyl),
(16) -CH_2-((3,5-bis-trifluoromethyl)phenyl),
(17) -CH_2-((3-fluoro-5-trifluoromethyl)phenyl),
(18) -$CH(CH_3)$-((3,5-bis-trifluoromethyl)phenyl), and
(19) -$C(CH_3)_2$-((3,5-bis-trifluoromethyl)phenyl). ~~;~~
~~(20) -CH_2-(4-(2-trifluoromethyl)pyridyl),~~
~~(21) -CH_2-(5-(3-trifluoromethyl)pyridyl),~~
~~(22) -CH_2-(5-(3-trifluoromethyl)pyridazinyl),~~
~~(23) -CH_2-(4-(2-trifluoromethyl)pyridyl-N-oxide), and~~
~~(24) -CH_2-(5-(3-trifluoromethyl)pyridyl-N-oxide).~~

26. (currently amended) The compound of Claim ~~1~~ 37 wherein R^3 is hydrogen ~~and~~ or phenyl,

where the phenyl is unsubstituted or substituted with 1-5 substituents ~~where the substituents are~~ independently selected from:

(a) halo,

(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$.

27. (currently amended) The compound of Claim ~~1~~ 37 wherein R^3 is hydrogen ~~and~~ or phenyl, where the phenyl is unsubstituted or substituted with 1-3 substituents ~~where the substituents are~~ independently selected from:

(a) halo,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl, and
(f) -CO_2R^9.

28. (currently amended) The compound of Claim ~~1~~ 37 wherein R^3 is phenyl, or para-fluorophenyl.

29. (currently amended) The compound of Claim ~~1~~ 37 wherein R^4 is selected from:

(a) hydrogen,
(b) hydroxy,
(c) -CO_2H,
(d) -CO_2C_{1-6}alkyl, and
(e) -CN.

Claims 30-31 (canceled).

32. (currently amended) A pharmaceutical composition which comprises an inert carrier and a compound of Claim ~~1~~ 37 .

33. (withdrawn) A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim ~~1~~ 37 .

34. (withdrawn) A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 37 .

35. (withdrawn) A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 37 .

36. (withdrawn) A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1~~ 37 .

37. (new) A compound of formula Ib, or a pharmaceutically acceptable salt or individual diastereomer thereof:



Ib

wherein:
the dashed line represents a single or a double bond;

Z is selected from:

C, N, and -O-, wherein when Z is N, then R^4 is absent, and when W is -O-, then both R^3 and R^4 are absent;

X is -CONH-;

R^2 is -CH_2-phenyl,

wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,

(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -CO_2-C_{1-3}alkyl,
(h) -CO_2H,
(i) -S-C_{1-3}alkyl,
(j) -SO_2-C_{1-3}alkyl,
(k) -SCF_3,
(l) -NH_2,
(m) -NH-SO_2-C_{1-3}alkyl, and
(n) -SO_2-NH_2;

R^3 is selected from H and -(C_{0-6}alkyl)-phenyl,

wherein alkyl is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl, and
(d) trifluoromethyl,

and wherein phenyl is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$;

R^4 is selected from the group consisting of:

(a) hydrogen,
(b) hydroxy,

(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -$CONR^9R^{10}$, and
(h) -CN;

or R^3 and R^4 may be joined together to form a ring which is selected from:

(a) 1H-indene,
(b) 2,3-dihydro-1H-indene,
(c) 2,3-dihydro-benzofuran,
(d) 1,3-dihydro-isobenzofuran,
(e) 2,3-dihydro-benzothiofuran, and
(f) 1,3-dihydro-isobenzothiofuran,

or R^3 and R^5 or R^4 and R^6 may be joined together to form a ring which is phenyl,

wherein the ring is unsubstituted or substituted with 1-7 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$;

R^9 and R^{10} are each independently selected from H and C_{1-6}alkyl;

R^5 and R^6 are each independently selected from the group consisting of:

(a) hydrogen,
(b) hydroxy,
(c) -CH_3,
(d) -O-CH_3, and
(e) oxo; or alternatively

R^5 is optionally selected from phenyl, 2-methylphenyl, -OH, benzyl, -NHBoc, and $-CO_2CH_3$; and R^6 is H;

R^{11} and R^{12} are H;

n is an integer selected from 0, 1 and 2; and

m is an integer selected from 1 and 2.

38. (new) The compound of Claim 37 which is selected from the group of the following compounds, or a pharmaceutically acceptable salt thereof:



Ex. 52



Ex. 78

39. (new) The compound of Claim 37, or a pharmaceutically acceptable salt or individual diastereomer thereof, selected from compounds having formula I and II below:



I

wherein each compound of formula I has the substituents shown in the table:

Ex.	R^3	R^4	R^5	n	Z
53	H	H	H	0	C
54	H	H	Ph	0	C
55	H	H	$PhCH_2$	1	C
56	H	H	OH	1	C
57	H	H	NHBoc	0	C
58	H	H	OH	0	C
59	H	H	o-MePh	0	C
60	H	$HOCH_2$	Ph	0	C

61	$PhCH_2CH_2CH_2$	OH	H	1	C
62	H	H	Ph	1	C
63	Ph	H	H	1	C
64	H	H	Ph	1	C
65	H	NHBoc	H	1	C
66	H	CO_2Me	H	1	C
67	H	H	CO_2Me	1	C
68	CO_2Me	None	H	1	N
69	Ph	None	H	1	N
70	None	None	H	1	O
71	H	H	H	2	C

; and



II

wherein each compound of formula II has the substituents shown in the table:

Ex.	R^{14}; R^{15}
76	
77	

40. (new) The compound of Claim 37, or a pharmaceutically acceptable salt or individual diastereomer thereof, wherein R^6 is H, and R^5 is selected from the group consisting of phenyl, 2-methylphenyl, -OH, benzyl, -NHBoc, and $-CO_2CH_3$.